NewAmsterdam Pharma (NASDAQ:NAMS) Research Coverage Started at HC Wainwright

HC Wainwright assumed coverage on shares of NewAmsterdam Pharma (NASDAQ:NAMS) in a research note released on Monday, MarketBeat Ratings reports. The firm issued a buy rating and a $48.00 target price on the stock. HC Wainwright also issued estimates for NewAmsterdam Pharma’s Q4 2024 earnings at ($0.37) EPS, FY2024 earnings at ($1.64) EPS, Q1 2025 earnings at ($0.45) EPS, Q2 2025 earnings at ($0.43) EPS, Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($1.88) EPS, FY2026 earnings at ($1.80) EPS, FY2027 earnings at ($1.78) EPS and FY2028 earnings at ($1.04) EPS.

Several other brokerages also recently issued reports on NAMS. Royal Bank of Canada reissued an “outperform” rating and set a $31.00 price objective on shares of NewAmsterdam Pharma in a research report on Thursday, September 5th. Needham & Company LLC reiterated a “buy” rating and set a $36.00 target price on shares of NewAmsterdam Pharma in a research note on Thursday, December 5th. Scotiabank boosted their price target on NewAmsterdam Pharma from $35.00 to $47.00 and gave the company a “sector outperform” rating in a research report on Wednesday, December 11th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $37.00 price objective on shares of NewAmsterdam Pharma in a research report on Monday, September 23rd. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, NewAmsterdam Pharma has an average rating of “Buy” and an average target price of $38.17.

NewAmsterdam Pharma Price Performance

NAMS stock opened at $25.70 on Monday. The business has a 50 day simple moving average of $22.26 and a 200-day simple moving average of $19.26. NewAmsterdam Pharma has a twelve month low of $11.18 and a twelve month high of $27.29.

Insider Buying and Selling

In related news, major shareholder Nap B.V. Forgrowth sold 33,438 shares of NewAmsterdam Pharma stock in a transaction that occurred on Thursday, December 26th. The stock was sold at an average price of $26.01, for a total value of $869,722.38. Following the sale, the insider now directly owns 10,727,490 shares in the company, valued at $279,022,014.90. The trade was a 0.31 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders sold 416,884 shares of company stock valued at $10,676,428 over the last ninety days. Corporate insiders own 19.50% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of NAMS. FMR LLC grew its stake in shares of NewAmsterdam Pharma by 35.6% during the 3rd quarter. FMR LLC now owns 330,412 shares of the company’s stock worth $5,485,000 after purchasing an additional 86,712 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in NewAmsterdam Pharma by 1,231.0% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 239,283 shares of the company’s stock worth $3,972,000 after buying an additional 221,305 shares in the last quarter. abrdn plc grew its position in NewAmsterdam Pharma by 69.8% during the third quarter. abrdn plc now owns 129,060 shares of the company’s stock worth $2,142,000 after buying an additional 53,060 shares during the period. Millennium Management LLC increased its holdings in NewAmsterdam Pharma by 23.0% in the second quarter. Millennium Management LLC now owns 1,165,429 shares of the company’s stock valued at $22,388,000 after buying an additional 217,902 shares in the last quarter. Finally, Jennison Associates LLC lifted its position in shares of NewAmsterdam Pharma by 8.9% during the 3rd quarter. Jennison Associates LLC now owns 1,020,278 shares of the company’s stock valued at $16,937,000 after acquiring an additional 83,115 shares during the period. Hedge funds and other institutional investors own 89.89% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.